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Effect of vitamin D metabolites on calcitriol metabolism in
experimental renal failure
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Effect of vitamin D metabolites on calcitriol metabolism in experimental
renal failure. Previous studies from our laboratory have demonstrated
that metabolic clearance rate (MCR) of calcitriol is decreased in
experimental renal failure. In this experiment, we examined the effects
of calcitriol, 25-hydroxyvitamin D3 (25(OH)D3) and 24,25-dihydroxyvi-
tamin D3 (24,25(OH)2D3) on the MCR of calcitriol in renal failure
produced in rats by partial nephrectomy. The MCR of calcitriol in these
rats with renal failure was significantly lower than in control rats with
sham operations. Plasma concentrations of calcitriol did not differ
between the rats with moderate renal failure and control rats (sham,
74.7 3.6 pg/mI, N = 7; renal failure, 67.7 6.0, N 6; serum
creatinine 0.56 0.02mg/dl vs. 0.96 0.02); however, the levels were
significantly lower in rats with severe renal failure (sham, 66.5 5.1
pg/ml, N = 7, severe renal failure, 49.6 2.1 pg/mI, N = 8; serum
creatinine 0.53 0.01 mgldl vs. 1.40 0.03). Subcutaneous infusion of
calcitriol (10 ng/kg/day) in rats with severe renal failure for one week
significantly increased the MCR of calcitriol (0.22 .01 vs. 0.17 .01
mI/mm/kg, P < 0.001). Infusion of 25(OH)D3 (600 ng/day) or
24,25(OH)2D3 (I .tg/day) in rats with renal failure for one week also
increased the MCR of calcitriol (25(OH)D3, 0.25 0.01 mI/mm/kg;
24,25(OH)2D3, 0.25 0.01, both P < 0.001) when compared to rats with
renal failure infused with vehicle (0.21 0.01). Administration of
24,25(OH)2D3 significantly lowered the plasma levels of calcitriol in rats
with renal failure (52.3 3.1 pg/mI, P < 0.05) in comparison to the rats
with renal failure infused with vehicle (67.7 6.0). The decreased
plasma levels of calcitriol were most likely due to the increase in MCR
following infusion of 24,25(OH)2D3. Treatment with 25(OH)D3 also
decreased the plasma levels of calcitriol (55.0 4.3 pg/mI) when
compared to the control rats with renal failure, but the decrease was not
statistically significant.
Catcitriol is primarily synthesized in the kidney by la-
hydroxylase, which has been identified in the mitochondria of
the proximal tubule [1], Therefore, synthesis of calcitriol would
be expected to decrease in patients with renal diseases. How-
ever, plasma concentrations of calcitriol often remain within
normal ranges in patients until the glomerular filtration rates
decrease below approximately 30 mI/mm [2, 3]. In addition,
plasma levels of calcitriol remain within normal values in
experimental renal failure produced by subtotal nephrectomy
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despite a decreased rate of calcitriol production [4]. We have
found that decreased MCR of calcitriol accounts for the main-
tenance of the normal levels of calcitriol in mild to moderate
renal failure, but the reason for the decreased metabolic clear-
ance of calcitriol is not entirely clear. The present study was
undertaken to examine the following factors which may influ-
ence the MCR.
The metabolic degradation of calcitriol is believed to be
regulated by calcitriol. It is proposed [5] that calcitriol associ-
ates with unoccupied receptors, and the calcitriol-occupied
receptor complex activates genes coding for vitamin D-induced
bioactive proteins and degradation enzymes, respectively,
which carry out the physiologic functions in various target
organs as well as inducing the production of degradation
enzymes. Thus, we studied the effect of calcitriol supplemen-
tation on its own metabolic clearance in renal failure, because
the decreased production of calcitriol in renal failure could, in
the same fashion, reduce its own degradation.
24,25-dihydroxyvitamin D3 (24,25(OH)2D3) has been re-
ported to lower the plasma concentrations of calcitriol in
animals fed a low calcium diet [6], it is thought, that by
enhancing the metabolic degradation of calcitriol. Since chronic
administration of 24,25(OH)2D3 to dogs with moderate renal
failure also significantly lowered the calcitriol plasma concen-
trations [7], suggesting that 24,25(OH)2D3 could lower the
plasma concentration by reducing production or increasing
metabolic clearance, we studied the effect of this vitamin D
metabolite on the metabolism of calcitriol in rats with renal
failure.
Finally, administration of 25(OH)D3 to patients with renal
failure increases plasma concentrations of 24,25(OH)2D3 [8].
Therefore, the possible effects of 25-hydroxyvitamin D3
(25(OH)D3) on calcitriol metabolism were also examined.
Methods
Experimental method
Male Sprague-Dawley rats weighing between 195 and 205 g
(Charles River Breeding Laboratories, Wilmington, Massachu-
setts, USA) were fed a diet containing 1.0% Ca, 0.8% P and
4,500 IU vitamin D3/kg and water ad libitum. Renal failure was
achieved by subtotal nephrectomy through bilateral flank inci-
sions as described previously [4]. One kidney was removed and
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the other kidney was partially resected. Control animals had
sham operation.
Effect of calcitriol on its own metabolic degradation in renal
failure
Two weeks after 5/6 subtotal nephrectomy and sham opera-
tion, one group of renal failure rats (N = 9) was continuously
infused with calcitriol for one week using osmotic minipumps
(Alza osmotic minipump, Model 2001, Alzet, Palo Alto, Cali-
fornia, USA) implanted subcutaneously. We have previously
determined that the average daily calcitriol production rates
(PR) for sham control rats and 5/6 nephrectomized rats were 25
ng/kg/day and 15 ng/kglday, respectively [4]. Thus the esti-
mated calcitriol PR was 10 ng/kg/day lower in renal failure rats.
Enough calcitriol to supply 10 ng/kg/day for one week was
dissolved in propylene glycol containing 1.25% of ethanol [9]
and infused subcutaneously into these animals. The actual
amount of calcitriol infused into each rat was verified by
measuring the residual volume in the minipump at the end of the
experiment. Another group of renal failure rats (N = 8) and
sham-operated control rats (N = 7) was infused with a vehicle
only delivered by osmotic minipumps. The MCR and PR of
calcitriol were measured one week after calcitriol or vehicle
infusion. Arterial blood samples were taken at the end of
3H-calcitriol infusion for measurement of plasma total calcium,
ionized calcium, phosphorus, creatinine, pH, pCO2, and endog-
enous plasma concentration of calcitriol. Urine was also col-
lected during the isotope infusion for creatinine measurement.
Effect of 24,25(OH)2D3 and 25(OH)D3 on the MCR of
calcitriol in renal failure
Since administration of 24,25(OH)2D3 and 25(OH)D3 may
lower plasma concentrations of calcitriol, a milder renal failure
was created in the following groups of animals, so that plasma
calcitriol levels would remain within normal range before the
infusion of vitamin D metabolites. Renal failure was achieved
by removal of one kidney and resection of half of the other
kidney. The following experiments were performed five days
after sham operation or partial nephrectomy.
Group 1 animals (N = 7), following sham nephrectomies,
were infused subcutaneously for seven days with a vehicle for
dissolving vitamin D metabolites (1.25% ethanol in propylene
glycol) by osmotic minipumps implanted subcutaneously be-
tween the scapulae.
Group 2 animals (N = 6) had subtotal nephrectomies and
were infused subcutaneously with vehicle in the same manner
as Group 1 rats.
Group 3 animals (N = 5) had subtotal nephrectomies and
were infused subcutaneously for seven days with 600 ng/day of
25(OH)D3 delivered by osmotic minipumps. The 25(OH)D3 was
dissolved in 1.25% ethanol in propylene glycol, and the dose
equaled the average daily PR in normal rats weighing 200 to 220
g [9].
Group 4 animals had subtotal nephrectomies and were in-
fused subcutaneously for seven days with 1 gig/day of 24,25
(OH)2D3 delivered by osmotic minipumps. The 24,25(OH)2D3
was dissolved in 1.25% ethanol in propylene glycol and deliv-
ered in an arbitrarily chosen dose based on a previous study
used in the rat [6].
The actual amounts of vitamin D metabolites infused into
each rat were verified at the end of the study by measuring the
residual volumes in the osmotic minipumps.
At the end of the experiment, arterial blood was withdrawn
for the measurements of ionized calcium, pH and pCO2, and
plasma concentrations of creatinine, total calcium, phosphate,
and calcitriol. Urine was also collected for creatinine measure-
ment.
Metabolic clearance of calcitriol was studied seven days after
the infusion of vitamin D metabolites as follows: On the day of
experimentation, the animals were anesthetized with ether. The
femoral artery was cannulated with a PE 50 tubing for blood
sampling, and the femoral vein was cannulated with PE 10 for
fluid infusion. In addition, a PE 50 tube was placed in the
bladder for urine collection. The animals were placed in indi-
vidual metabolic cages and allowed to awaken before the
experiment. The MCR of calcitriol was measured by the tech-
nique of constant infusion of radiolabeled calcitriol, as we have
previously described [4]. Radioactive calcitriol (l,25(26,27-
3H-dihydroxyvitamin D3), specific activity 160 Ci/mmol, and
96% purity) in ethanol was dissolved in 0.5 ml of pooled rat
plasma and diluted with a sufficient volume of normal saline to
infuse intravenously at a rate of 0,0025 ml/min/100 g body
weight for 19 hours. Animals were fasted during the isotope
infusion. The amount of radiolabeled calcitriol infused into each
rat, 0.0025 MCi/hour, was less than 2% of the estimated endog-
enous PR in a normal rat. Blood samples (0.6 ml) were
withdrawn at 17 and 19 hours after beginning the isotopic
infusion and centrifuged immediately. The plasma was sepa-
rated from the red blood cells and immediately frozen at —20°C
until radioactive calcitriol was determined. The red blood cells
were mixed with an equivalent volume of normal saline and
returned to each rat.
The plasma level of radioactive calcitriol was determined as
previously described [10, 11]. Briefly, 200 microliters of thawed
plasma were brought to one ml by the addition of normal saline.
Cold calcitriol, 300 ng in 50 d absolute ethanol, was added to
monitor recovery. Plasma protein was precipitated using one ml
of acetonitrile followed by vigorous vortexing and centrifuga-
tion. The supernatant was combined with 0.5 ml K2HPO4 (0.4
M, pH 10.6) and applied to a LC-18 column. The column was
eluted with 5 ml of distilled water, 3 ml of 70% methanol and 5
ml of acetonitrile. The last fraction, containing vitamin D
metabolites, was dried under nitrogen. The residue was dis-
solved in 500 jd of HPLC solvent containing 88% hexane, 10%
isopropanol, and 2% methanol. Radioactive calcitriol was sep-
arated from the other metabolites using an HPLC solvent
delivery system (Spectra Physics SP 8710, San Jose, California,
USA). Calcitriol recovery averaged 69%. We have demons-
trated that the straight phase HPLC system separated calcitriol
from l,24,25(OH)3D3, calcitroic acid, and l,25,26(OH)3D3. Fur-
thermore, the peak of radioactivity comigrating with calcitriol
on straight phase HPLC eluted as a single radioactive peak that
coeluted with standard calcitriol on a reverse phase system
(20% water in methanol) using a 5 m C-l8 analytical column
with excellent recovery [12]. The mobile phase used in this
study is also reported to separate calcitriol from l,25(OH)2D3,
26,23-lactone, 1 ,23,25(OH)3D3, 24-oxo- 1 ,25(OH)2D3, 23-oxo- 1,
25(OH)2D3, 24-oxo-1,23,25(OH)3D3, and other vitamin D
metabolites [11].
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Group I Control 245 0.53 0.48 9.63 4.63 7.57 7.41 33.7
N = 7 ±5.7 ±0.01 ±0.02 ±0.06 ±0.04 ±0.13 ±0.01 ±2.02
Group 2 RF 251 1.40 0.21 9.69 4,62 7.64 7.40 36.3
N = 8 ±5.3 ±0.03 ±0.01 ±0.08 ±0.02 ±0.13 ±0.01 ± 1.55
Group 3 RF + Calcitriol 222 1.37 0.19 10.22 4.77 7.57 '1.40 36.0
N = 9 ±9.4 ±0.02 ±0.01 ±0.09 ±0.05 ±0.11 ±0.01 ± 1.78
F value 4.72 766.85 65.65 17.44 5.38 1.21 0.24 0.57
P value 0.025 0.001 0.001 0.001 0.025 NS NS NS
Comparisons
1—2 NS <0.001 <0.001 NS NS NS NS NS
l—3 <0.05 <0.001 <0.001 <0.001 <0.05 NS NS NS
2—3 <0.05 NS NS <0,001 <0.05 NS NS NS
Abbreviations: N, number of animals; RF, renal failure; Sr, serum creatinine; C, creatinine clearance; Ca and Pc", total plasma calcium








Group I Sham control(N = 7)
66.5 ± 5.1 0.25 ± 0.01 24.3 ± 2.3
Group 2 RF 49.6 ± 2.1 0,17 ± 0.01 12.3 ± .55(N 8)
Group 3 RF + calcitriol(N = 9)
67.5 ± 4.0 0.22 ± 0.01 21.4 ± 1.7
F 6.86 48.17 14.36
P 0.01 0.001 0.001
Comparisons
1—2 <0.01 <0.001 <0.001
1—3 NS <0.005 NS
2—3 <0.005 <0.001 <0.001
Results
Effect of ca/c/trial supplementation on calcitriol metabolism
Table I summarizes renal functions and plasma concentra-
tions of calcium and phosphorus, as well as blood pH and pCO2
levels. Renal function was decreased comparably in nephrecto-
mized rats. Plasma concentrations of phosphorus were similar
among the three groups. Total plasma and ionized calcium
concentrations of rats with renal failure supplemented with
calcitriol were slightly, but significantly, higher than those of
control rats with renal failure without calcitriol supplementa-
tion.
The effects of calcitriol supplementation on calcitriol metab-
olism in rats with renal failure are shown in Table 2. The MCRs
of rats with renal failure supplemented with calcitriol were
significantly increased, in comparison to rats with renal failure
not supplemented with calcitriol, although the values were still
significantly lower than those of control rats. Plasma concen-
Table 2. Metabolic clearance of calcitriol in renal failure rats
supplemented with control
The MCR of calcitriol was calculated as:
MCR = Infusion rate of 3H-calcitriol
The mean study state plasma concentrations of 3H-calcitriol
PR of calcitriol was calculated as:
PR = MCR x endogenous plasma concentration of caicitriol
The plasma concentrations of tracer reached a steady state
after 17 hours of isotopic infusion, and the average coefficient of
variation for the plasma counts of radiolabeled calcitriol from
the 17- and 19-hour samples was less than 3%. Since there is no
difference in the calculated MCRs at 17 and 19 hours, only the
average values of 17 and 19 hours are presented in this study.
Analytical methods
Plasma concentrations of creatinine and phosphorus were
determined as previously described [13]. Total plasma calcium
was determined by atomic absorption spectrophotometry
(Model 306, Perkin Elmer, Norwalk, Connecticut, USA). Ion-
ized calcium was measured by a NOVA Model 6 electrode
(NOVA Biochemical, Newton, Massachusetts, USA). Blood
pH and pCO2 were measured by an IL 713 pH/blood gas
analyzer (Instrumentation Lab Inc., Lexington, Massachusetts,
USA). Plasma concentration of calcitriol was determined after
the separation of plasma calcitriol from 25(OH)D3, 24,25
(OH)2D3, and 1,24,25(OH)D3 using a HPLC solvent delivery
system. The HPLC solvent contains 88% hexane, 10% isopro-
panol, and 2% methanol which completely separates calcitriol
from the other vitamin D metabolites [II]. Plasma calcitriol was
measured in duplicate by a commercially available radiorecep-
tor assay kit (INCSTAR, Stillwater, Minnesota, USA). Our
interassay coefficients of variation were 13.4% for the low
standard (N = 12) and 11.8% for the high standard (N = I!).
Calcitriol was not detectable in the water blanks. Recovery of
calcitriol after the extraction procedures average 64%.
All data are expressed as mean ± SEM. Statistical analysis
was performed using Duncan's multiple range test [14], and a P
value of less than 0.05 was considered significant.
Abbreviations are: MCR, metabolic clearance; PR, production rate,
others are similar in Table I. UThe calculated PR is the sum of
endogenous PR and exogenous infusion (10 ng/kg/day).
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Table 3. Renal function and plasma concentrations of calcium, phosphorus and blood pH and pCo2 in partially nephrectomized rats











Group I Control 308 0.56 0.48 9.79 4.64 8.27 7.41 33.40N 7 ±3.4 ±0.02 ±0.02 ±0.16 ±0.02 ±0.17 ±0.01 ± 1.74
Group 2 RF 219 0.96 0.32 9.90 4.63 8.23 7.42 35.00
N = 6 ±6.5 ±0.02 ±0.01 ±0.15 ±0.04 ±0.12 ±0.01 ± 1.59
Group 3 RF 225 0.97 0.31 9.96 4.61 89.20 7.43 35.70
+25-(OH)D3 ±8.1 ±0.02 ±0.01 ±0.14 ±0.05 ±0.01 ±0.01 ±2.12N= 5
Group 4 RF 217 0.95 0.31 9.70 4.71 7.87 7.43 34.20
+24,25-(OH)2D3 ±4.9 ±0.02 ±0.02 ±0.14 ±0.07 ±0.11 ±0.01 ±1.46N=6
F value 68.5 139.20 32,70 0,56 0.90 2.09 1.39 0.32
P value 0.001 0.001 0.001 NS NS NS NS NS
Comparisons
1 vs. 2 <0.001 <0.001 <0.001 NS NS NS NS NS
I vs. 3 <0.001 <0.001 <0.001 NS NS NS NS NS
I vs.4 <0.001 <0.001 <0.001 NS NS NS NS NS
2 vs. 3 NS NS NS NS NS NS NS NS
2 vs. 4 NS NS NS NS NS NS NS NS
3 vs. 4 NS NS NS NS NS NS NS NS
Abbrevia tions as in Table 1.
trations of calcitriol were significantly lower in rats with renal
failure not supplemented with calcitriol, when compared to
those of the other two groups. The values of the latter two
groups, however, were not different. The calculated calcitriol
PRs of rats with renal failure not supplemented with calcitriol
were significantly lower than those of the other two groups
which had the same calculated levels.
Effects of 24,25(OH)2D3 and 25(OH)D3 on calcitriol
metabolism
Renal function and plasma concentrations of total calcium,
ionized calcium, phosphorus, and arterial blood pH and pCO2
are presented in Table 3. Body weight was significantly higher
in the sham-operated control animals. Renal functions were
equally reduced in all three groups of animals following subtotal
nephrectomy. There were no differences in plasma total cal-
cium, ionized calcium, phosphorus, and arterial blood pH and
pCO2 among the four groups of animals.
Plasma concentrations of calcitriol, MCR, and PR of cal-
citriol are presented in Table 4. The plasma levels of calcitriol
were not different between the sham-operated control rats and
the rats with renal failure infused with vehicles, However, the
concentrations of calcitriol were significantly reduced in rats
with renal failure infused with 25(OH)D3 and 24,25(OH)2D3,
when compared to the sham-operated control rats. The mean
levels of calcitriol in rats with renal failure infused with
24,25(OH)2D3 and 25(OH)D3 were also lower than in rats with
renal failure infused with a vehicle, although only with
24,25(OH)2D3 was there statistical significance.
The MCR of rats with renal failure infused with a vehicle was
significantly lower than that of sham-operated control rats
infused with a vehicle. Administration of vitamin D metabo-
lites, 25(OH)D3 and 24,25(OH)2D3, significantly improved the
MCRs of rats with renal failure, although the MCRs still
remained lower than in sham-operated control rats. The calcu-
lated PRs of calcitriol in renal failure rats with or without
Table 4. Metabolic clearance of calcitriol in renal failure rats








Group I Control 74.7 0.27 29.3
N = 7 ±3.6 ±0.01 ±1.9
Group 2 RF 67.7 0.21 20.2
N = 6 ±6.0 ±0.01 ±1.7
Group 3 RF 55.0 0.25 19.6
+ 25-(OH)D3 ±4.3 ±0.01 ±1.8
N= 5
Group 4 RF 52.3 0.25 I9.I
+ 24,25-(OH)2D3 ±3.1 ±0.01 ±1.4N=6
F 5.9 17.5 8.8
P 0.001 0.001 0.001
Comparisons
I vs. 2 NS <0.001 <0.005
I vs. 3 <0.01 <0.05 <0.001
I vs. 4 <0.005 <0.05 <0.001
2 vs. 3 NS <0.001 NS
2 vs. 4 <0.05 <0.001 NS
3vs.4 NS NS NS
Abbreviation as in Table 2.
supplementations of vitamin D metabolites were also greatly
decreased when compared to sham-operated control rats. The
calcitriol PRs of the three groups of rats with renal failure were
not different.
Discussion
Since kidneys are the primary source of calcitriol synthesis,
plasma concentrations of calcitriol fall as renal failure pro-
gresses in patients with renal diseases. However, a large
number of patients are able to maintain normal plasma levels of
calcitriol, especially when their glomerular filtration rates are
above 40 mI/mm [2, 31. It is suggested that the elevation of
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parathyroid hormone (PTH) may stimulate 1 a-hydroxylase and
lead to the compensatory production of calcitriol by the remain-
ing nephron [15]. Although PTH is a potent stimulator of
1 a-hydroxylase [1], plasma levels of calcitriol were not different
between unilaterally nephrectomized rats and sham operated
rats with or without acute parathyroidectomy [161. The levels
were also not different between chronic thyroparathyroidecto-
mized (TPTX) rats with subtotal nephrectomy and with sham
operation of nephrectomy [17]. Factors other than secondary
hyperparathyroidism, therefore, are thought to play an impor-
tant role in maintaining plasma concentrations of calcitriol in
moderate renal failure. For example, dietary phosphate intake
can modulate plasma concentrations of calcitriol [18, 19].
Restriction of phosphate intake in children with moderate renal
failure normalizes their plasma levels of calcitriol [201. It is
possible that the dietary intake of phosphate could partly
explain the normal levels of calcitriol in patients with renal
failure [21]. Evidence suggests that 1 a-hydroxylase activity is
increased in intact kidneys when the contralateral kidney is
damaged [22]. However, the enzyme activity is also suppressed
when the animal developed severe renal failure [22].
Previous studies from our laboratory have demonstrated that
the synthesis of calcitriol was decreased in rats with renal
failure produced by partial nephrectomy. Further, concomitant
decreased metabolic clearance of calcitriol, resulted in normal
plasma levels of calcitriol [4]. Although the reasons for the
decreased metabolic clearance are not entirely clear, we have
found that the metabolic clearance of calcitriol in normal rats
could be suppressed by uremia achieved by urine infusion [23].
TPTX with or without infusion of physiologic dose of PTH in
rats with renal failure did not improve the metabolic clearance
of calcitriol [17].
The metabolic degradation of calcitriol is believed to be
receptor mediated. It is proposed that calcitriol associates with
unoccupied receptor, and the complex activates gene coding for
induction of degradation enzymes [5]. Maierhofer et al [24]
reported that the MCR of calcitriol appeared to be accelerated
when its synthesis was increased. In vitro studies have shown
that calcitriol suppressed 1 a-hydroxylase and induced 24-hy-
droxylase, which could accelerate its own degradation [25—271.
Frolick and DeLuca have demonstrated that predosing vitamin
D-depleted rats with calcitriol increased the rate of disappear-
ance of calcitriol from plasma and tissues [28]. Therefore, the
decreased calcitriol production of renal failure could, in the
same fashion, reduce its own degradation. We have shown that
calcitriol supplementation in rats with renal failure indeed
improved the MCRs of calcitriol; however, the values remained
lower than in normal rats.
In a preliminary study [6], 24,25(OH)2D3 administered orally
in a dose of ito 10 gJ 100 g daily for four weeks to rats fed a low
calcium diet markedly reduced the plasma concentrations of
calcitriol. It was thought that 24,25(OH)2D3 lowered plasma
calcitriol by enhancing its metabolic degradation. Further,
chronic administration of 24,25(OH)2D3 to dogs with moderate
renal failure also significantly lowered the calcitriol plasma
concentrations [7], even though plasma levels of 24,25(OH)2D3
of dogs with renal failure were not significantly lower than the
controls. In the present study, we found that supplementation
of 24,25(OH)2D3 also significantly lowered the plasma concen-
trations of calcitriol and increased the MCR of calcitriol in rats
with renal failure, although the values of MCR remained lower
than in the sham-operated control rats. Thus, we believe the
increased MCR of calcitriol is primarily responsible for the
lower plasma levels of calcitriol following the administration of
24,25(OH)2D5 in renal failure.
Administration of 25(OH)D3 to patients with chronic renal
failure and anephric patients resulted in marked elevation of
plasma concentrations of 24,25(OH)2D3 [8]. Therefore, supple-
mentation of 25(OH)D3 in rats with renal failure may also raise
the plasma levels of 24,25(OH)2D3 and improve the MCR of
renal failure. Several studies have demonstrated that adminis-
tration of 25(OH)D3 raised plasma concentrations of calcitriol in
patients with chronic renal failure and end stage renal disease
[8, 29, 30]. Increased synthesis of calcitriol following the
administration of 25(OH)D3 could accelerate the MCR of renal
failure. In the present study we showed that the MCRs associ-
ated with renal failure were improved by 25(OH)D3 treatment
without change in plasma levels or syntheses of calcitriol.
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